EpCAM-positive CTCs have been reported to be associated with aggressive features of HCC, such as vascular invasion, elevated serum AFP (≥400 ng/mL), and a more advanced BCLC stage [45,46]. This evidence concerns the gene AFP and hepatocellular carcinoma.